Investors love to see shares of the companies they own beating the market over, say, 10 years or more. But when that happens, there is always the worry that a corporation doesn't have much left in its growth tank.

Take Vertex Pharmaceuticals (NASDAQ: VRTX), a biotech that has delivered market-beating returns over the past decade. The drugmaker is still at it even amid the market downturn and currently sits near its 52-week high. Vertex has certainly been impressive, but are the company's best days already in the rearview mirror? Let's find out. 

Continue reading

Source Fool.com